[HTML][HTML] Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a …
…, V Siarheyeva, S Kazlouskaya, A Khorau… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background The purpose of this trial is to evaluate the safety and efficacy of ELENAGEN, a
novel anticancer therapeutic DNA plasmid encoding p62/SQSTM1 protein, as an adjuvant to …
novel anticancer therapeutic DNA plasmid encoding p62/SQSTM1 protein, as an adjuvant to …
Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant …
…, A Filimonava, V Siarheyeva, S Kazlouskaya, A Khorau… - 2023 - ascopubs.org
e17540 Background: We recently reported on the efficacy of the p62/SQTM1-encoding plasmid
in patients with advanced, recurrent platinum-resistant ovarian cancer (PROC) receiving …
in patients with advanced, recurrent platinum-resistant ovarian cancer (PROC) receiving …
Results of neoadjuvant chemotherapy in patients with breast cancer
A Khorau - The Breast, 2011 - thebreastonline.com
Results: The general objective answer on neoadjuvant chemotherapy is revealed at 18
patients (72%), stabilisation-at 7 patients (28%), cancer progressing were not. Thus the general …
patients (72%), stabilisation-at 7 patients (28%), cancer progressing were not. Thus the general …
What is New About Sentinel Node Biopsy in Breast Cancer (2011 Update)
S Beressa - The Breast, 2011 - thebreastonline.com
Objective: To evaluate the effectiveness of clinical examination in the diagnosis of early breast
cancer in women presented with breast mass in comparison with fine needle aspiration …
cancer in women presented with breast mass in comparison with fine needle aspiration …
Development of Personalized management in Metastatic Breast Cancer at resource poor area: A comprehensive definition developed by Rajasthan Cancer cure …
SC Sanchetee, S Sanchetee - The Breast, 2011 - thebreastonline.com
Results: Patients' age ranged from 22 to 34 years, with a mean age of 30.8 years. For the
tumor diameter, the patients were classified into 6 at T0, 18 at T1, 31 at T2, 8 at T3, and 3 at T4. …
tumor diameter, the patients were classified into 6 at T0, 18 at T1, 31 at T2, 8 at T3, and 3 at T4. …
Clinicopathological Study of Breast Cancer in Young Women
M Iwamoto, N Sato, H Fujioka, Y Takahashi… - The …, 2011 - thebreastonline.com
Results: Patients' age ranged from 22 to 34 years, with a mean age of 30.8 years. For the
tumor diameter, the patients were classified into 6 at T0, 18 at T1, 31 at T2, 8 at T3, and 3 at T4. …
tumor diameter, the patients were classified into 6 at T0, 18 at T1, 31 at T2, 8 at T3, and 3 at T4. …
[HTML][HTML] Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized …
D Kaidarova, E Zhavrid, O Shatkovskaya… - Cancer Treatment and …, 2024 - Elsevier
Aim To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin)
administered either with a single-use injection device (SID) or manually from a vial using a hand-…
administered either with a single-use injection device (SID) or manually from a vial using a hand-…
